Skip to main content
Innovations Inspired by
life
Search
Menu
Search
Hamburger
Our Company
Who we are
History
Culture
Board of Directors
Leadership Team
OUR RESEARCH
Therapeutic focus
Delivery Technologies
Research Programs
R&D Pipeline
Our Medicines
Xelpros®
Elepsia® XR
Business Development
Strategy
Partner with us
Accreditations And Approvals
Good Laboratory Practice
Investors
Who we are
Financials
Annual reports
Presentations
Chairman's Speech
Committees of BOD's
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
Board of Directors
FAQ’s, Guide Book and Forms for Shareholders
Investors Contact
Go green
IEPF
Media
Press Releases
Presentations
Careers
Overview
Apply Now
Contact Us
Media
»
Press Releases
Media
Press Releases
Presentations
Press Releases
10-Dec-2021
SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting
08-Dec-2021
SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma
03-Dec-2021
SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
26-Nov-2021
SPARC to Provide Update on Clinical Programs and R&D Pipeline
14-May-2021
SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension
14-Oct-2020
SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery
22-Sep-2020
SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics
19-Aug-2020
SPARC to Provide Update on R&D Pipeline
28-May-2020
SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma
13-Feb-2020
SPARC to Provide Update on TaclantisTM NDA
Pagination
Current page
1
Page
2
Page
3
Page
4
Next page
››
Last page
Last »
